JP2023508328A5 - - Google Patents

Info

Publication number
JP2023508328A5
JP2023508328A5 JP2022538220A JP2022538220A JP2023508328A5 JP 2023508328 A5 JP2023508328 A5 JP 2023508328A5 JP 2022538220 A JP2022538220 A JP 2022538220A JP 2022538220 A JP2022538220 A JP 2022538220A JP 2023508328 A5 JP2023508328 A5 JP 2023508328A5
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
cancer
pharmaceutically acceptable
pharmaceutical product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022538220A
Other languages
English (en)
Japanese (ja)
Other versions
JP7631348B2 (ja
JP2023508328A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/065409 external-priority patent/WO2021127044A1/en
Publication of JP2023508328A publication Critical patent/JP2023508328A/ja
Publication of JP2023508328A5 publication Critical patent/JP2023508328A5/ja
Application granted granted Critical
Publication of JP7631348B2 publication Critical patent/JP7631348B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022538220A 2019-12-20 2020-12-16 組み合わせ Active JP7631348B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962952039P 2019-12-20 2019-12-20
US62/952,039 2019-12-20
PCT/US2020/065409 WO2021127044A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (3)

Publication Number Publication Date
JP2023508328A JP2023508328A (ja) 2023-03-02
JP2023508328A5 true JP2023508328A5 (cg-RX-API-DMAC7.html) 2023-12-26
JP7631348B2 JP7631348B2 (ja) 2025-02-18

Family

ID=76478095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538220A Active JP7631348B2 (ja) 2019-12-20 2020-12-16 組み合わせ

Country Status (12)

Country Link
US (1) US20230008362A1 (cg-RX-API-DMAC7.html)
EP (1) EP4069235A4 (cg-RX-API-DMAC7.html)
JP (1) JP7631348B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220119442A (cg-RX-API-DMAC7.html)
CN (1) CN115427042A (cg-RX-API-DMAC7.html)
AU (1) AU2020407070A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012281A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165472A1 (cg-RX-API-DMAC7.html)
IL (1) IL294080A (cg-RX-API-DMAC7.html)
MX (1) MX2022007626A (cg-RX-API-DMAC7.html)
TW (1) TW202132299A (cg-RX-API-DMAC7.html)
WO (1) WO2021127044A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020018286A2 (pt) 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
WO2021097139A1 (en) 2019-11-15 2021-05-20 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
KR20230038523A (ko) 2020-07-09 2023-03-20 리커리엄 아이피 홀딩스, 엘엘씨 Wee1 억제제의 염 및 형태
WO2023083194A1 (zh) * 2021-11-09 2023-05-19 杭州格博生物医药有限公司 Wee1蛋白激酶降解剂及其用途
JP2024546584A (ja) * 2021-12-15 2024-12-26 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Bcl-2阻害剤、wee-1阻害剤及び他の化学療法剤の三剤療法の組み合わせ
WO2025193930A1 (en) * 2024-03-14 2025-09-18 Zeno Management, Inc. Wee1 inhibitor combination therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015183776A1 (en) 2014-05-29 2015-12-03 Merck Sharp & Dohme Corp. Methods for treating cancer with a wee1 inhibitor
MX2020001235A (es) * 2017-08-01 2020-07-20 Recurium Ip Holdings Llc Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
CN109422754A (zh) * 2017-08-24 2019-03-05 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
IL316472A (en) 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
BR112020018286A2 (pt) 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
JP2024546584A (ja) * 2021-12-15 2024-12-26 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Bcl-2阻害剤、wee-1阻害剤及び他の化学療法剤の三剤療法の組み合わせ

Similar Documents

Publication Publication Date Title
JP2023508332A5 (cg-RX-API-DMAC7.html)
JP2021516242A5 (cg-RX-API-DMAC7.html)
JP7759877B2 (ja) 治療用化合物
JP7348906B2 (ja) フェロトーシス誘導活性を有する化合物およびそれらの使用方法
CN101941970B (zh) 用于治疗癌症的meleimide衍生物、药物组合物以及方法
JP2020517616A5 (cg-RX-API-DMAC7.html)
JP2024530495A5 (cg-RX-API-DMAC7.html)
RU2007134396A (ru) Химические соединения
EP3999507B1 (en) Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonsits
JP2023507797A5 (cg-RX-API-DMAC7.html)
JP2023526283A5 (cg-RX-API-DMAC7.html)
JP2023508327A5 (cg-RX-API-DMAC7.html)
RU2017145026A (ru) Соединение, ингибирующее brk
JP2006507253A5 (cg-RX-API-DMAC7.html)
JP2008505167A5 (cg-RX-API-DMAC7.html)
RU2020102453A (ru) Фармацевтические композиции
RU2013107007A (ru) Бифункциональные соединения, являющиеся ингибиторами rho-киназы, композиция и применение
JP2014511840A5 (cg-RX-API-DMAC7.html)
JP2006519862A5 (cg-RX-API-DMAC7.html)
JPWO2020032105A5 (cg-RX-API-DMAC7.html)
KR20210102942A (ko) 치환된 아릴메틸우레아 및 헤테로아릴메틸우레아, 이의 유사체, 및 이의 사용 방법
JP2022521818A5 (cg-RX-API-DMAC7.html)
RU2009114731A (ru) Производное пиразолопиримидина
RU2006106768A (ru) Новые ингибиторы фарнезилпротеинтрансферазы как противоопухолевые агенты
RU2009131834A (ru) Производные 3-циннолинкарбоксамида и их применение для лечения рака